Proactive Investors - Run By Investors For Investors

Orgenesis CEO Vered Caplan says it's a 'very exciting time' for cell therapy in Fox interview

'I think it’s very impressive how globally regulatory agencies have taken on the challenge of finding a way to get these drugs to patients,' Caplan said in an interview on 'Mornings with Maria'
scientists in a lab
Orgenesis is a developer and manufacturer of advanced cell therapies

Vered Caplan, the CEO of Orgenesis Inc (NASDAQ:ORGS), a developer of advanced cell therapies, said her business is undergoing a “very exciting time” thanks to regulators working together to get cell therapies to patients, according to a Fox Business Network interview on the program “Mornings with Maria” held on Thursday.

“I think it’s very impressive how globally regulatory agencies have taken on the challenge of finding a way to get these drugs to patients,” Caplan said on the program.

"It’s exciting to see how scientists and regulatory people around the world are working together. Even a bone marrow transplantation is a cell therapy,” added Caplan.

READ: Orgenesis seals pact with Ben-Gurion University to develop dissolvable carriers for cell culturing

Developing cell therapies offers up challenges as it’s impossible to devise them as you would a plastic or a chemical material. “Making these drugs, making these products is the biggest engineering challenge so to speak,” Caplan said on Fox. “This is living material. These are the cells of our body.”

A developer and manufacturer of advanced cell therapies, Orgenesis is building a unique and fundamental base platform of know-how and expertise for a multitude of cell types and for the regenerative medicine industry. Based in Germantown, Maryland, the company conducts much of its research in Belgium and has also recently opened an operation in Korea. 

Orgenesis shares held steady at $5.17 in Thursday’s morning trading session.


View full ORGS profile View Profile

Orgenesis Timeline

Related Articles

September 25 2018
A decision on whether or not Motif can start marketing its next-generation antibiotic in the US is due by mid-February
Hep C
November 22 2018
The company made positive operational progress in the year to June 30.
January 15 2019
Under former chief executive Peter George and his successor Shaun Chilton, Clinigen has been transformed via a series of well-judged, quickly integrated and cash generative acquisitions
Copyright ©, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use